BRIEF published on 04/21/2026 at 15:14, 24 days ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 24 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 1 month 14 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 1 month 14 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 1 month 14 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 1 month 15 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 3 months 25 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
PRESS RELEASE published on 01/20/2026 at 18:30, 3 months 25 days ago Inside Information / Other news releases MaaT Pharma announces first patient randomized in IMMUNOLIFE Phase 2 study sponsored by Gustave Roussy to explore the role of gut microbiome in overcoming ICI resistance in NSCLC patients with antibiotic-induced dysbiosis NSCLC MaaT Pharma Gut Microbiome Antibiotic-induced Dysbiosis IMMUNOLIFE
BRIEF published on 12/10/2025 at 11:30, 5 months 5 days ago MaaT Pharma SACA Maintains Positive Outlook as Phase 3 Trial Data Strengthens Buy Recommendation Phase 3 Trial MaaT Pharma Xervyteg GI-aGvHD
PRESS RELEASE published on 12/10/2025 at 11:25, 5 months 5 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates recommendation to BUY for MaaT Pharma SACA with a target price of €17 following positive phase 3 trial results for Xervyteg presented at ASH Annual Meeting 2025 First Berlin Equity Research Buy Recommendation ASH Annual Meeting Xervyteg MaaT Pharma SACA
Published on 05/15/2026 at 14:35, 54 minutes ago NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Published on 05/15/2026 at 14:30, 59 minutes ago AIAI Holdings Corporation Expresses Appreciation to Revere Securities for Financial Advisory Support on Successful NASDAQ Direct Listing
Published on 05/15/2026 at 14:00, 1 hour 29 minutes ago CCL Industries Announces 2026 Annual and Special Shareholders' Meeting Results
Published on 05/15/2026 at 14:00, 1 hour 29 minutes ago First Canadian Graphite to Attend the Mining Investment Event in Quebec City
Published on 05/15/2026 at 14:00, 1 hour 29 minutes ago Underground Gold Potential Grows at Colosseum
Published on 05/15/2026 at 15:15, 14 minutes ago Game On for esports jobs: 65% globally demand more education and career pathways for pro gaming
Published on 05/15/2026 at 14:46, 43 minutes ago Original-Research: MBB SE (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 05/15/2026 at 15:08, 21 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/13/2026 at 17:45, 1 day 21 hours ago Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.
Published on 05/13/2026 at 17:45, 1 day 21 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026
Published on 05/13/2026 at 17:40, 1 day 21 hours ago Report on share repurchases from 6 to 12 May 2026
